TWIST BIOSCIENCE CORP (TWST)
US90184D1000 - Common Stock
We assign a fundamental rating of 4 out of 10 to TWST. TWST was compared to 581 industry peers in the Biotechnology industry. While TWST has a great health rating, there are worries on its profitability. TWST shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
TWST had negative earnings in the past year.
In the past year TWST has reported a negative cash flow from operations.
TWST had negative earnings in each of the past 5 years.
In the past 5 years TWST always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -27.34%, TWST is in the better half of the industry, outperforming 72.88% of the companies in the same industry.
TWST has a Return On Equity of -34.30%. This is in the better half of the industry: TWST outperforms 76.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.34% | ||
| ROE | -34.3% | ||
| ROIC | N/A |
ROA(3y)-23.56%
ROA(5y)-32.67%
ROE(3y)-28.87%
ROE(5y)-39.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 38.29%, TWST is doing good in the industry, outperforming 77.89% of the companies in the same industry.
TWST's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TWST so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.74%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TWST has more shares outstanding
The number of shares outstanding for TWST has been increased compared to 5 years ago.
TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 7.78 indicates that TWST is not in any danger for bankruptcy at the moment.
TWST has a Altman-Z score of 7.78. This is amongst the best in the industry. TWST outperforms 83.07% of its industry peers.
There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.78 |
ROIC/WACCN/A
WACC9.19%
2.3 Liquidity
TWST has a Current Ratio of 5.51. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
TWST has a Current ratio of 5.51. This is comparable to the rest of the industry: TWST outperforms 55.96% of its industry peers.
TWST has a Quick Ratio of 5.06. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
TWST has a Quick ratio of 5.06. This is comparable to the rest of the industry: TWST outperforms 53.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.06 |
3. Growth
3.1 Past
TWST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.98%, which is quite good.
Looking at the last year, TWST shows a very strong growth in Revenue. The Revenue has grown by 21.79%.
The Revenue has been growing by 57.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.04%
Revenue 1Y (TTM)21.79%
Revenue growth 3Y39.6%
Revenue growth 5Y57.36%
Sales Q2Q%25.13%
3.2 Future
TWST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.83% yearly.
The Revenue is expected to grow by 21.79% on average over the next years. This is a very strong growth
EPS Next Y8.68%
EPS Next 2Y11.46%
EPS Next 3Y11.83%
EPS Next 5YN/A
Revenue Next Year25.38%
Revenue Next 2Y22.76%
Revenue Next 3Y21.79%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TWST. In the last year negative earnings were reported.
Also next year TWST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y11.83%
5. Dividend
5.1 Amount
No dividends for TWST!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TWIST BIOSCIENCE CORP
NASDAQ:TWST (5/31/2024, 7:10:51 PM)
After market: 41.9 0 (0%)41.9
+1.07 (+2.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.44B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.34% | ||
| ROE | -34.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)16.98%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y8.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.79%
Revenue growth 3Y39.6%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y